The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease

Study Overview
=================
Brief Summary
-----------------
In this study, typical cases of blood stasis syndrome of coronary heart disease are selected, by using microRNA chip, cDNA microarray and other bioinformatics technologies to filter and verify related miRNA and its target gene of Coronary Heart disease. Meanwhile, intervene by Xuesaitong soft capsules to investigate related miRNA and its target gene of Coronary Heart disease.

Official Title
-----------------
The Analysis of Blood Stasis Syndromeand of Coronary Heart Disease Related MicroRNA Genomics and Target Gene Regulatory Networks

Conditions
-----------------
Coronary Heart Disease, Unstable Angina, Blood Stasis Syndrome

Intervention / Treatment
-----------------
* Drug: Xuesaitong soft capsule
* Drug: Xuesaitong soft capsule Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of coronary angiography unstable angina Clinical diagnosis of unstable angina Age of 30 to 75 years old Not use thrombolysis, dilate coronary drugs within two weeks Tongue dark Sign the consent Exclusion Criteria: Severe valvular heart disease Insulin-dependent diabetes mental disease Combined with severe liver, kidney, hematopoietic system disorder Patients with malignant tumors Pregnancy or breast-feeding women Recent history of trauma Drug allergy

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Xuesaitong soft capsule group<br>Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule. | Drug: Xuesaitong soft capsule<br>* Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.<br>|
| Placebo Comparator: control group<br>Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo. | Drug: Xuesaitong soft capsule Placebo<br>* Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina | The change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina by real RT-PCR. | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MicroRNA, coronary heart disease, unstable angina, blood stasis syndrome, Xuesaitong soft capsule